Company Overview and News
2018-09-06 seekingalpha - 1
Wallace Weitz's 13F portfolio value decreased marginally from $2.37B to $2.35B this quarter. The number of positions increased from 75 to 79.
ALSN DLTR WEHIX LBTYK RWT MSFT BATRA MLM LSXMB FB TMO CCV LSXMA QVCB CCZ QVCA AGN EQCO AAPL MON TUP DEO LBRDB MUSA TDG LBTYB MA AXTA LBTYA LBRDK PRSP CCV.CL LSXMK LBRDA TXN DISCB DISCA KMX LBTY DISCK CAXPF HPE AMZN LILAB SUM DXC CMCSK DISC EQC LGF GWRE TWC BRK.A GOOGL LILAK XOXO FLIR MHK WFCNP BATRK BATRR GOOG CHTR LVNTB ACN LVNTA BATRB DXC.WI XOMA ORCL MKL WFC ACIW FWONB CFX CMCSA QRTEA FWONA INS V BKNG PX OCLCF FWONK LGF.A LGF.B DHR LILA
2018-09-02 seekingalpha - 9
Soros' 13F portfolio value increased from $6.16B to $6.25B this quarter. The number of positions decreased from 219 to 203.
VR LRCX DISCB DISCA NOW TWX DISCK INXN VICI CRM AMZN EQT AABA AET DISC BAC SIGM LGF KWN.CL UTX AIG TWC COUP CZR RNG XLGLF QCOM LIVN FG TIVO WFCNP TMO XL NFLX BAX BAC KW KWN CI GM LBRDB WFC EA C ZAYO CACQ COL LBRDK I TGT LIVN ETFC CNQ CVX LGF.A LBRDA LGF.B SBAC
2018-08-19 seekingalpha - 2
SQ Advisors has just eleven positions. The top three holdings are CarMax, Allison Transmission, and Brookfield Asset Management, and they add up to ~36% of the entire portfolio.
KMX LBTY HXL ALSN CAXPF TYLE CHTR LBTYK TYL LILAB AAPL BAM LBRDB CABO BAMGF BBU LBTYB AXTA LBTYA LBRDK BRK.A SCHW HXL LILAK LBRDA SBAC BAMKF LILA
No one has to make asset allocation or security selection decisions. You can save up cash in federally insured savings accounts and max out tax-advantaged accounts with passive, low-cost ETFs pegged to indexes such as the S&P 500 (SPY). For most investors and investment dollars, this is a perfectly adequate solution. Want a better than adequate solution? There are a handful of publicly-traded companies run by people who have proved their abilities to beat the market over the long-term.
LBRDB BRK.A FB CFX TWX LBRDA DJCO TWC LBRDK AET DHR MANU
Ladies and gentlemen, thank you for standing by. Welcome to the GCI Liberty 2018 Q2 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded, August 8.
LBRDB LBRDA LBRDK
Ladies and gentlemen, thank you for standing by. Welcome to the GCI Liberty 2018 Q2 Earnings Call. During the presentation all participants will be in a listen-only mode. Afterwards we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded August 8.
LBRDB LBRDA LBRDK
Good morning. My name is Michelle, and I will be your conference operator today. At this time, I would like to welcome everyone to Charter's second quarter 2018 investor call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.
LBRDB CHTR LBRDA TWC LBRDK
2018-07-13 seekingalpha - 2
"The greatest shortcoming of the human race is our inability to understand the exponential function." -Albert Bartlett
LBRDB LSXMB BATRK FWONB AAL LSXMA BATRR LBRDK FWONA VA AN CHTR FWONK BATRB LSXMK LBRDA DAL BATRA TIVO
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM DOV.WI NOV TEL CVS FNF BAC CHTR APY.WI FNFV DOV GM ORCL LBRDB BAC C AAL BHGE COMM MA ARNC TWC LBRDK BHI CGBBW OCLCF JLL LBRDA FL APY UNH
2018-07-11 seekingalpha - 1
The Oakmark Global Fund’s three-month return declined 0.3%, compared to a 1.7% return for the MSCI World Index during the period and the Lipper Global Fund Index’s gain of 0.4%.
DGLD LBTY NOV UAA TEL GOOG IPG CS CHTR UGLD LBTYK LILAB GM LUV CNHI LBRDB DSLV VIIX CSSLF VIIZ LBTYB MA LBTYA ARNC DDAIF RB LBRDK UA CSGKF GOOGL LILAK ZIV RBGLY LBRDA USLV TVIX THC TV XIV LILA
Geico’s former chief investment officer, Lou Simpson, was at one point seriously considered by Warren Buffett as a possible successor to the long-time Berkshire Hathaway Inc. (NYSE:BRK.A, NYSE:BRK.B) CEO. Simpson retired in 2010, but he grew bored of life away from the office and set up SQ Advisors, a Naples-based investment advisory firm with his wife Kimberly Querrey.
LSXMB BATRK CCV LSXMA BATRR CCZ CHTR AAPL BATRB CMCSK ST LBRDB FWONB AKZA CMCSA LBRDK FWONA BRK.A CCV.CL FWONK LSXMK LBRDA SBAC BATRA
2018-05-29 seekingalpha - 2
Wallace Weitz's 13F portfolio value decreased marginally from $2.40B to $2.37B. The number of positions decreased from 77 to 75.
ALSN DLTR WEHIX LBTYK RWT FOX RRS BATRA MLM LSXMB LH FB TMO CCV LSXMA QVCB CCZ GLIBA QVCA AGN EQCO AAPL MON TUP DEO LBRDB MRVL TDG MUSA LBTYB MA AXTA LBTYA LBRDK AON RGRYY JPM CCV.CL LSXMK LBRDA TXN DISCA KMX LBTY PXD CAXPF HPE AMZN LILAB CMP DXC CMCSK EQC LGF LEXEA GWRE TWC RGRLF RRC BRK.A GOOGL LILAK KTN XOXO FLIR AHBIF FOXA WFCNP BATRK BATRR RRL GOOG CHTR LVNTB VMC ACN LVNTA BATRB DXC.WI XOMA ORCL MKL WFC WAIR BUD ACIW FWONB CFX CMCSA QRTEA FWONA INS V BKNG PX OCLCF FWONK LGF.A LGF.B DHR LILA
2018-05-28 seekingalpha - 2
Ruane, Cunniff & Goldfarb’s 13F portfolio value decreased ~11% from $12.20B to $10.91B. The number of positions decreased from 66 to 59.
NPSNY BMCH KMX RYCEY CAXPF TJX AMZN STCK VIVHY OMC AABA RYCEF BLDR COF-P IAC WSCC SEQUX BRK.A PRI GOOGL MHK FCAU JD WFCNP FB IBKR WUBA GOOG COF-D GS COF-C COF-F JEC CNSWF WFC LBRDB WSBF MA COF LBRDK FWONA W V BKNG SCHW XRAY CACC FWONK WAT LBRDA ORLY
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET